What was the primary driver of revenue growth in the quarter?

Revenue growth was primarily driven by strong performance across all three business segments: Medical, Diagnostics, and Biosciences. The Medical segment saw growth in areas like Medical Surgical Systems and Diabetes Care. The Diagnostics segment benefited from safety-engineered product sales, and the Biosciences segment experienced growth from instrument sales like the BD FACSCanto™ analyzer and flow cytometry reagents. International sales, particularly in Europe, also contributed positively, partly due to favorable foreign currency translation.

How did the adoption of SFAS No. 123(R) impact the financial results?

Effective October 1, 2004, Becton Dickinson adopted SFAS No. 123(R) for share-based compensation. This new accounting standard requires the recognition of compensation cost using a fair-value measurement method. For the quarter ending December 31, 2004, the company recorded $11.6 million in share-based compensation expense, which reduced diluted earnings per share from continuing operations by $0.03. Prior periods were not restated, and the company provided pro-forma disclosures for comparison.

What is the outlook for the company's financial performance, and what are the key growth strategies?

The company anticipates continued revenue growth over the next three years, driven by core business expansion (including safety-engineered devices), global sales of high-quality products, and the development of new products across its segments. Management is focused on increasing revenue growth through beneficial products, improving operating effectiveness and balance sheet productivity, and strengthening organizational capabilities. The company also expects improvement in gross profit margin and selling and administrative expense ratios for fiscal year 2005.

Are there any significant legal or contingent liabilities that investors should be aware of?

The company is involved in various legal proceedings, both as plaintiff and defendant, which arise in the ordinary course of business, including product liability and environmental matters. While the company believes its defenses are valid and that these proceedings should not have a material adverse effect, management acknowledges the uncertain nature of litigation and the potential for charges exceeding reserves, which could materially impact future results of operations and cash flows. A more detailed discussion is available in the company's 2004 Form 10-K and within this report.

BDX 10-Q Quarterly Report Q1 FY2005 — Revenue, Net Income, EPS

Summary

Becton, Dickinson and Company (BDX) reported strong financial results for the quarter ending December 31, 2004, demonstrating robust revenue growth and improved profitability. Total revenues increased by 8.7% to $1.29 billion, driven by solid performance across all three segments: Medical, Diagnostics, and Biosciences. The company's strategic focus on innovative products and operational efficiency is yielding positive outcomes, with operating income significantly increasing year-over-year. Key financial improvements include a substantial rise in income from continuing operations, which more than doubled compared to the prior year's quarter, leading to a significant increase in both basic and diluted earnings per share. The company also reported strong operating cash flow and made progress in strengthening its balance sheet by reducing its debt-to-capitalization ratio. While the company adopted new accounting standards for share-based compensation, impacting reported expenses and EPS, the underlying operational performance remains strong.

Key Highlights

1Revenue growth of 8.7% to $1.29 billion, with Medical, Diagnostics, and Biosciences segments all contributing positively.
2Income from continuing operations surged by 55.6% to $194.4 million, resulting in a significant increase in EPS.
3Diluted earnings per share from continuing operations rose to $0.74, a substantial improvement from $0.48 in the prior year.
4Operating income increased significantly, reflecting improved gross profit margins and effective cost management.
5Net cash provided by continuing operating activities was strong at $257.1 million, supporting capital expenditures and debt management.
6Debt-to-capitalization ratio improved to 25.6% from 28.1% in the prior quarter, indicating a strengthening balance sheet.
7The company adopted SFAS No. 123(R) for share-based compensation, resulting in an expense of $11.6 million and a reduction of $0.03 in diluted EPS for the quarter.

BECTON DICKINSON & CO Quarterly Report for Q1 Ended Dec 31, 2004

Summary

Key Highlights

Frequently Asked Questions